Hematologic Malignancy
Conditions
Keywords
leukemia, myelodysplastic syndrome, lymphoma, minimal residual disease, BPX-501, AP1903, rimiducid
Brief summary
Phase I, open-label, non-randomized study of safety, pharmacokinetics and efficacy of donor BPX-501 T cell infusion in children with recurrent or minimal residual disease (MRD) hematologic malignancies post-allogeneic transplant. The study will consist of the Main Study and an optional Pharmacokinetics (PK) Sub-Study.
Detailed description
Main Study: Approximately 16 subjects will participate in the BPX-501 main study. The treatment consists of three courses of BPX-501 T cell infusions at 30 day intervals with 2 escalating dose levels (DL). DL1 on Day 0; DL2 on Days 30 and 60. Two doses of rimiducid (AP1903) will be investigated for the treatment of aGvHD after BPX-501 T cell infusion. A 0.1mg/kg initial dose of rimiducid which has demonstrated the ability to induce \>50% BPX-501 T cell eradication in preclinical animal models will first be administered in the event of uncontrollable aGvHD. If there is no response to this dose within 24hrs + 12hrs a second dose of 0.4 mg/kg (which has been reported to induce T cell eradication of \> 90%) will be administered. If there is no measurable GvHD response to the initial dose of 0.1 mg/kg rimiducid in 2 subjects, the starting dose of rimiducid will be 0.4 mg/kg for all subsequent subjects. Rimiducid (AP1903) Optional PK Sub-Study: Approximately 12 subjects will be recruited to participate in the optional Rimiducid (AP1903) PK sub-study. Subjects will be assigned to one of two arms and receive either 0.04mg/kg or 0.4mg/kg of Rimiducid (AP1903). Each arm will have a target enrollment of 6 subjects. * Arm 1: 0.04mg/kg Rimiducid (AP1903), 6 subjects; * Arm 2: 0.4mg/kg Rimiducid (AP1903), 6 subjects. Rimiducid PK samples and ECG data will be collected at Pre-dose (0 hour), 30 minutes, 2 hours and 8 hours following the initiation of rimiducid (AP1903) infusion. Efforts shall be made to enroll at least one subject from each age subset into the PK sub-study: infants and toddlers (12 months to 23 months); children (2-11 years); and adolescents (12-18 years).
Interventions
BIOLOGICALBPX-501 T cells
Biological: T cells transduced with CaspaCIDe® safety switch
DRUGrimiducid
administered to eliminate BPX-501 cells in the event of GVHD
Sponsors
Bellicum Pharmaceuticals
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
1 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* Patients aged \< 18 * Clinical diagnosis of one of the following pediatric hematological malignancies: * High-risk Acute Leukemia (Acute lymphoblastic leukemia \[ALL\] or acute myeloid leukemia \[AML\]) in any CR * Acute Leukemia that is minimal residual disease (MRD) positive at \> 1copy per 1 x 10,000 reference copies pre-HSCT * Myelodysplastic Syndrome (MDS) * Hodgkin or Non-Hodgkin lymphomas * Other high-risk hematological malignancy in CR eligible for stem cell transplantation per institutional standard * Patients with a hematological malignancy who have received a prior allogeneic HSCT * Patients with on-treatment relapse of AML within 6 months of initial CR * Patients relapsing within 6 months of initial diagnosis of hematological malignancy. * Planned or previous treatment of hematological malignancy with one of the following: * Matched related HSCT * Mismatched related HSCT * For patients who have received a transplant, occurrence of one of the following \> 30 days post-HSCT: * Minimal residual disease (MRD) positive at \> 1 copy per 1 x 10,000 reference copies post-HSCT * Decreasing donor chimerism detected on two bone marrow biopsies or peripheral blood analyses at a \> 7-day interval * Recurrent disease * Life expectancy \>10 weeks; * Signed donor and patient/guardian informed consent; * For mismatched related donor recipients, a minimum genotypic identical match of 5/10 is required, as determined by high resolution typing, at least one allele of each of the following genetic loci must be matched: HLA-A, HLA-B, HLA-C, HLA- DRB1, and HLA-DQB1. * Performance status: Karnofsky/Lansky score \> 70%. * Adequate organ function as measured by: * High-risk Acute Leukemia (Acute lymphoblastic leukemia \[ALL\] or acute myeloid leukemia \[AML\]) in any CR * High-risk Acute Leukemia (Acute lymphoblastic leukemia \[ALL\] or acute myeloid leukemia \[AML\]) in any CR * Hepatic: direct bilirubin ≤ 3x ULN, or AST/ALT ≤ 5x ULN. * Bone marrow; * \> 25% donor T cell chimerism * ANC \>1 x 10\^9/L. * Cardiac: LVEF at rest \>45%. * Pulmonary: FEV 1, FVC, DLCO (diffusion capacity for CO) \> 50% predicted (corrected for hemoglobin); for children who are unable to perform pulmonary function tests due to age or developmental ability, there must be no evidence of dyspnea or no need for supplemental oxygen as evidenced by 02 saturation ≥ 92% on room air. * Hepatic: direct bilirubin ≤ 3x ULN, or AST/ALT ≤ 5x ULN. * Renal: creatinine clearance ≤ 2x of ULN for age
Exclusion criteria
≥ Grade II acute GVHD or moderate to severe chronic GVHD due to a previous allograft at the time of screening; * Active CNS involvement by malignant cells (\< 2 months prior to time of consent); * Current uncontrolled bacterial, viral or fungal infection (currently taking medication with evidence of progression of clinical symptoms or radiologic findings). * Positive HIV serology or viral RNA; * Pregnancy (positive serum βHCG test) or breast-feeding female; * Patients of reproductive age unwilling to use effective forms of birth control or abstinence for a year after BPX-501 T cell infusion.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| BPX-501 Safety | Month 24 | Incidence of treatment emergent adverse events of 2 stratified dose levels of BPX-501 T cell infusions based on patient-donor match in pediatric subjects with hematologic malignancies |
| Mean plasma concentration | pre-dose, 30 min, 2 hours and 8 hours after start of infusion | Measure plasma concentrations of rimiducid (AP1903) at two doses (Arm 1: 0.04mg/kg; Arm 2: 0.4mg/kg) in pediatric subjects, during and after a 2-hour infusion |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | Month 24 | Measure overall survival rates after BPX-501 infusion |
| Response Rate | Month 24 | Assess response rates after BPX-501 infusion |
Countries
Italy
Outcome results
None listed